The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma

Virology
Tetiana HutchisonRobert L Harrod

Abstract

The human T-cell leukemia virus type-1 (HTLV-1) is an oncoretrovirus that infects and transforms CD4+ T-cells and causes adult T-cell leukemia/lymphoma (ATLL) -an aggressive lymphoproliferative disease that is highly refractive to most anticancer therapies. The HTLV-1 proviral genome encodes several regulatory products within a conserved 3' nucleotide sequence, known as pX; however, it remains unclear how these factors might cooperate or dynamically interact in virus-infected cells. Here we demonstrate that the HTLV-1 latency-maintenance factor p30II induces the TP53-induced glycolysis and apoptosis regulator (TIGAR) and counters the oxidative stress, mitochondrial damage, and cytotoxicity caused by the viral oncoproteins Tax and HBZ. The p30II protein cooperates with Tax and HBZ and enhances their oncogenic potential in colony transformation/foci-formation assays. Further, we have shown that TIGAR is highly expressed in HTLV-1-induced tumors associated with oncogene dysregulation and increased angiogenesis in an in vivo xenograft model of HTLV-1-induced T-cell lymphoma. These findings provide the first evidence that p30II likely collaborates as an ancillary factor for the major oncoproteins Tax and HBZ during retroviral carcin...Continue Reading

References

Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·L J Zhao, C Z Giam
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·I J KoralnikG Franchini
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·W J GrossmanL Ratner
Sep 30, 1994·Science·H Hermeking, D Eick
Mar 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·D SaggioroL Chieco-Bianchi
Apr 18, 2001·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·T M WillcoxM G Sarr
Aug 8, 2001·International Journal of Experimental Pathology·J M JohnsonG Franchini
Oct 11, 2002·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Tetsuhiko NomuraSeiichiro Watanabe
May 31, 2003·EMBO Reports·Scott R FrankBruno Amati
Aug 30, 2003·Seminars in Diagnostic Pathology·Jeffery L Kutok, Christopher D M Fletcher
Jan 20, 2004·Nature Medicine·Christophe NicotGenoveffa Franchini
Feb 21, 2004·AJR. American Journal of Roentgenology·Fumito OkadaHiromu Mori
Dec 2, 2004·Molecular and Cellular Biology·Jagruti H PatelSteven B McMahon
Mar 10, 2005·Journal of Cell Science·Patrick HivinJean-Michel Mesnard
Jan 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yorifumi SatouMasao Matsuoka

❮ Previous
Next ❯

Citations

Dec 20, 2019·Retrovirology·Ramona MolesGenoveffa Franchini
Jul 25, 2021·International Journal of Molecular Sciences·Helga Simon-MolasAnna Manzano
Aug 8, 2021·International Journal of Molecular Sciences·Greta ForlaniMaria Grazia Romanelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.